<DOC>
	<DOC>NCT02605265</DOC>
	<brief_summary>The study evaluate the addition of Irinotecan in neoadjuvant chemoradiation. Half of participants will receive capecitabine alone together with neoadjuvant CRT, followed by a cycle of XELOX, while the other will receive capecitabine and irinotecan during CRT, followed by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after the completion of CRT, then 5 cycles of adjuvant chemotherapy of XELOX.</brief_summary>
	<brief_title>Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>pathological confirmed adenocarcinoma clinical stage T34 and/or N+ the distance from anal verge less than 12 cm without distance metastases KPS &gt;=70 UGT1A1*28 6/6 or 6/7 without previous anticancer therapy sign the inform consent pregnancy or breastfeeding women serious medical illness baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN DPD deficiency UGT1A1*28 7/7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoadjuvant Chemoradiation</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>UGT1A1</keyword>
</DOC>